VYNE Therapeutics (VYNE) Invested Capital (2020 - 2021)

VYNE Therapeutics (VYNE) posted Invested Capital of $33.4 million for Q2 2021, up 69.97% on a QoQ basis from $19.6 million in Q1 2020.

VYNE Therapeutics (VYNE) Invested Capital (2020 - 2021) Analysis & Trends

VYNE Therapeutics' Invested Capital history runs 2 years deep, the most recent figure standing at $33.4 million for Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 110.96 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 116.14 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 VYNE Therapeutics 1.19 Bn 1.16 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2021 33.38 Mn
Mar 31, 2020 19.64 Mn